Windward Bio Debuts on Nasdaq, Shares Surge 68% on IPO Day
Clinical-stage biotech Windward Bio priced its IPO at $17 and closed its first trading day at $28.50 on Nasdaq.
Windward Bio, a clinical-stage biotechnology company backed by Qiming Venture Partners, made its Nasdaq debut on November 13, 2026, with shares closing sharply higher than their offering price on the first day of trading.
The Shanghai-rooted biotech priced its initial public offering at $17.00 per share under the ticker symbol WWB. By the closing bell, shares had climbed to $28.50, representing a gain of roughly 68 percent from the IPO price — a strong first-day performance by any measure in the current biotech capital markets environment.
Read more IQSTEL Posts $313M Nine-Month Revenue on 34.5% Organic Growth →
Windward Bio operates in the immunology space, a therapeutic area that has drawn sustained investor interest as drugmakers pursue next-generation treatments for autoimmune and inflammatory conditions. The company's listing adds to a growing cohort of Asia-linked biotechs seeking access to U.S. public capital markets through Nasdaq.
Qiming Venture Partners, a prominent venture firm with deep roots in Chinese technology and life-sciences investing, is listed as a key backer of the newly public company. The firm's involvement signals institutional confidence in Windward Bio's clinical pipeline, though the source does not detail specific pipeline assets or trial-stage data.
The IPO underscores continued appetite among investors for clinical-stage biotech offerings despite broader market volatility, particularly in the immunology segment. Continue reading at All Financial Services & Investing.